DE60117873D1 - Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen - Google Patents

Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen

Info

Publication number
DE60117873D1
DE60117873D1 DE60117873T DE60117873T DE60117873D1 DE 60117873 D1 DE60117873 D1 DE 60117873D1 DE 60117873 T DE60117873 T DE 60117873T DE 60117873 T DE60117873 T DE 60117873T DE 60117873 D1 DE60117873 D1 DE 60117873D1
Authority
DE
Germany
Prior art keywords
submicroparticle
suspensions
producing
pharmaceutical substances
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117873T
Other languages
English (en)
Other versions
DE60117873T2 (de
Inventor
E Kipp
Chung Wong
J Doty
L Rebbeck
Sean Brynjelsen
Jane Werling
Rajaram Sriram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/874,799 external-priority patent/US6607784B2/en
Priority claimed from US09/953,979 external-priority patent/US6951656B2/en
Priority claimed from US10/035,821 external-priority patent/US6977085B2/en
Priority claimed from US10/021,692 external-priority patent/US6884436B2/en
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of DE60117873D1 publication Critical patent/DE60117873D1/de
Publication of DE60117873T2 publication Critical patent/DE60117873T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
DE60117873T 2000-12-22 2001-12-20 Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen Expired - Lifetime DE60117873T2 (de)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US874637 1986-06-16
US874499 1986-06-16
US35821 1998-03-06
US25816000P 2000-12-22 2000-12-22
US258160P 2000-12-22
US09/874,799 US6607784B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US874799 2001-06-05
US09/874,637 US6869617B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,499 US7037528B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US953979 2001-09-17
US09/953,979 US6951656B2 (en) 2000-12-22 2001-09-17 Microprecipitation method for preparing submicron suspensions
US10/035,821 US6977085B2 (en) 2000-12-22 2001-10-19 Method for preparing submicron suspensions with polymorph control
US10/021,692 US6884436B2 (en) 2000-12-22 2001-12-12 Method for preparing submicron particle suspensions
US21692 2001-12-12
PCT/US2001/049737 WO2002055059A2 (en) 2000-12-22 2001-12-20 Method for preparing submicron particle suspensions

Publications (2)

Publication Number Publication Date
DE60117873D1 true DE60117873D1 (de) 2006-05-04
DE60117873T2 DE60117873T2 (de) 2006-08-24

Family

ID=27567644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117873T Expired - Lifetime DE60117873T2 (de) 2000-12-22 2001-12-20 Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen

Country Status (16)

Country Link
EP (2) EP1642571A3 (de)
JP (1) JP4376518B2 (de)
CN (1) CN100512798C (de)
AT (1) ATE319432T1 (de)
AU (2) AU2002249836B2 (de)
BR (1) BR0116377A (de)
CA (1) CA2431705C (de)
DE (1) DE60117873T2 (de)
DK (1) DK1347747T3 (de)
ES (1) ES2260337T3 (de)
HU (1) HUP0501030A3 (de)
IL (1) IL156310A0 (de)
MX (1) MXPA03005496A (de)
NO (1) NO20032860L (de)
NZ (1) NZ526608A (de)
WO (1) WO2002055059A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
WO2004096180A1 (en) * 2003-04-29 2004-11-11 Baxter International Inc. Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
AU2004249172A1 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
MXPA06000720A (es) * 2003-07-18 2006-08-23 Baxter Int Metodos para fabricacion, usos y composiciones de particulas esfericas pequenas preparadas por separacion de fase controlada.
CA2534471A1 (en) * 2003-08-06 2005-02-17 Eisai Co., Ltd. Method and apparatus for producing ultrafine drug particles
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
EP1727520A2 (de) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Verfahren zur herstellung von mischphasen-kokristallen mit wirkstoffen
EP1713443A2 (de) * 2004-01-29 2006-10-25 Baxter International Inc. Nanosuspensionen von antiretroviralen mitteln für die verbesserte abgabe an das zentrale nervensystem
EP1731138B1 (de) * 2004-03-31 2016-03-23 Toyama Chemical Co., Ltd. Feine dispersion eines schwerlöslichen arzneimittels und herstellungsverfahren dafür
MXPA06011171A (es) 2004-06-15 2007-01-25 Baxter Int Aplicacion ex-vivo de agentes terapeuticos microparticulados solidos.
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
WO2006101972A2 (en) * 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
US20070134341A1 (en) * 2005-11-15 2007-06-14 Kipp James E Compositions of lipoxygenase inhibitors
ES2447465T3 (es) 2008-03-05 2014-03-12 Baxter International Inc. Partículas de superficie modificada y métodos para la administración dirigida de fármacos
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
MX2012010868A (es) 2010-03-22 2013-02-26 Mjr Pharmjet Gmbh Procedimiento y dispositivo para la preparacion de micro o nanoparticulas.
CN102384973B (zh) * 2011-08-10 2014-09-10 华南理工大学 快速定量检测羟甲基糠醛的免疫层析试纸条及其制备方法
CN102268103B (zh) * 2011-09-02 2013-06-05 中国海洋大学 一种壳聚糖醋酸盐的制备方法
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
CN103212079A (zh) * 2013-04-26 2013-07-24 陆媛 一种预防和/或治疗感冒的含服药物组合物及其应用
CN104905262B (zh) * 2015-05-29 2017-12-22 湖北省农业科学院农产品加工与核农技术研究所 一种制备虫草灵芝复合制剂的方法
KR101725508B1 (ko) * 2015-07-31 2017-04-11 국방과학연구소 헥사나이트로스틸벤 입자의 제조 방법과 그 장치
CN105969316B (zh) * 2016-06-03 2020-11-10 宁海德宝立新材料有限公司 一种用于热敷的相变储热复合材料
CA3030308C (en) 2016-07-29 2022-04-05 The Board Of Trustees Of Western Michigan University Magnetic nanoparticle-based gyroscopic sensor
CN108031142A (zh) * 2017-12-13 2018-05-15 上海合全药物研发有限公司 一种简化的利用湿磨来制备大量微晶种的装置及方法
CN115349630A (zh) * 2022-06-20 2022-11-18 海宁凤鸣叶绿素有限公司 水分散性叶黄素微囊粉的制备方法
WO2024136660A1 (en) * 2022-12-22 2024-06-27 Nanomi B.V. Process for preparing stable nanoparticle and composition thereof
WO2024153857A1 (en) 2023-01-18 2024-07-25 Nanoform Finland Oyj A method for crystallization of active pharmaceutical ingredients
CN116143803A (zh) * 2023-01-29 2023-05-23 山东省分析测试中心 一种大颗粒头孢哌酮钠球形晶体的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
FI973804A (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
WO1999033467A1 (en) * 1997-12-31 1999-07-08 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
EP1079808B1 (de) * 1998-05-29 2004-02-11 Skyepharma Canada Inc. Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
EP1104291B1 (de) * 1998-07-17 2005-09-07 Janssen Pharmaceutica N.V. Granulat mit einem fungizid und einem polymer umhüllten kern
DE60023465T2 (de) * 1999-03-24 2006-07-20 R.P. Scherer Technologies, Inc., Las Vegas Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
EP1642571A3 (de) 2007-06-27
CA2431705C (en) 2010-10-05
AU2002249836B2 (en) 2006-12-14
EP1347747B1 (de) 2006-03-08
IL156310A0 (en) 2004-01-04
JP2004538249A (ja) 2004-12-24
BR0116377A (pt) 2005-12-13
CN1505503A (zh) 2004-06-16
NO20032860D0 (no) 2003-06-20
CA2431705A1 (en) 2002-07-18
DK1347747T3 (da) 2006-04-10
DE60117873T2 (de) 2006-08-24
CN100512798C (zh) 2009-07-15
EP1642571A2 (de) 2006-04-05
ATE319432T1 (de) 2006-03-15
WO2002055059A3 (en) 2002-09-06
AU2006201943A1 (en) 2006-06-01
JP4376518B2 (ja) 2009-12-02
NO20032860L (no) 2003-08-21
NZ526608A (en) 2006-06-30
EP1347747A2 (de) 2003-10-01
HUP0501030A3 (en) 2008-04-28
ES2260337T3 (es) 2006-11-01
MXPA03005496A (es) 2004-05-14
HUP0501030A2 (en) 2007-02-28
WO2002055059A2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
ATE319432T1 (de) Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
DE60222734D1 (de) Mikropartikel und Verfahren zur deren Herstellung
DE60009326D1 (de) Verfahren zur herstellung von silicoaluminophosphat-molekularsieben
DE69002905D1 (de) Verfahren zur Herstellung von lipidischen Mikropartikeln.
ATE353081T1 (de) Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
DE69919599D1 (de) Verfahren zur herstellung von 4-trifluormethylsulfinylpyrazolderivat
ATE256458T1 (de) Verfahren zur mikroverkapselung von wasserlöslichen substanzen
DE602005026827D1 (de) Verfahren zur herstellung von isoindolderivaten
DE60227630D1 (de) Verfahren zur Herstellung von Fullerene
ATE299858T1 (de) Verfahren zur herstellung von diaminodiphenylmethan und seiner höheren homologen
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
ATE440846T1 (de) Verfahren zur herstellung von chloriden von phthalocyaninderivaten, die wenigstens eine quaternäre ammoniumgruppe enthalten
DE69918050D1 (de) Verfahren zur herstellung von (2r, 3s)-amino-1,2-oxiran
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
ATE317259T1 (de) Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
ATE519748T1 (de) Verfahren zur herstellung von chinazolin-4-on und derivaten davon
YU59401A (sh) Postupak za proizvodnju alendronske kiseline
ATE384067T1 (de) Verfahren zur herstellung von 3-cephemderivaten
ATE342254T1 (de) Verfahren zur herstellung von derivaten von [(1,5-diaryl)pyrazol-3-ylöpropansäure
DE60004850D1 (de) Verfahren zur herstellung von (r) und (s)-aminocarnitin und deren derivative aus d- und l-aspargin säure
DE60207042D1 (de) Verfahren zur herstellung einer wässrigen zellulosederivat-dispersion
ATE285393T1 (de) Verfahren zur herstellung von (r)-2-brom-3- phenylpropionsäure
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
ATE360086T1 (de) Verfahren zur herstellung von avermectinderivaten
ATE171937T1 (de) Verfahren zur herstellung von diazomethanderivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition